Close Menu

NEW YORK (GenomeWeb News) – Affymetrix today announced a deal with Massachusetts General Hospital to co-develop cancer biomarker tests using Affy's QuantiGene ViewRNA Assay platform.

As part of the deal, Affy has the commercialization rights to new tests resulting from the collaboration. Other terms were not disclosed.

The QuantiGene ViewRNA Assay is an in situ hybridization assay with single-transcript in single-cell detection capability. The platform is for research-use only.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.